This study explored the use of high-flow nasal oxygen (HFNO) in both pre-oxygenation and apnoeic oxygenation in adults who were intubated following a non-rapid sequence induction. Fifty patients were randomised to receive pre-oxygenation via a standard facemask or the Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) device. After five minutes of pre-oxygenation, induction and muscle relaxant agents were given. While waiting for complete paralysis, patients in the standard facemask group received bag-mask ventilation (BMV), whereas patients in the HFNO group received apnoeic oxygenation via the THRIVE device. Serial blood samples for arterial blood gas analysis were taken. Baseline patient and airway characteristics were similar. The median PaO 2 after pre-oxygenation was 357 (interquartile range ) mmHg in the facemask group, compared to 471 ) mmHg in the HFNO group (P=0.01). The median arterial partial pressure of oxygen (PaO 2 ) in the HFNO group decreased after a period of apnoeic oxygenation, and was significantly lower when compared to patients who received BMV in facemask group. The arterial carbon dioxide partial pressure (PaCO 2 ) level after complete paralysis was significantly higher in the HFNO group when compared to the facemask group (median 52 [IQR 48-55 {range 40-65}] versus median 43 [IQR 40-48 {range 35-63}] mmHg, P=0.0005 and P=0.004 respectively). There were no differences in the time to muscle paralysis and time to intubation. Seven patients required use of airway adjuncts during BMV in the facemask group, compared to none in the HFNO group (P=0.004). No complications were observed in either group. HFNO produces a higher PaO 2 after pre-oxygenation and safe PaO 2 during intubation. However, the subsequent fall in PaO 2 and rise in PaCO 2 indicates that it is not as effective as BMV in maintaining oxygenation and ventilation following neuromuscular blockade.
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Summary
This study explored the use of high-flow nasal oxygen (HFNO) in both pre-oxygenation and apnoeic oxygenation in adults who were intubated following a non-rapid sequence induction. Fifty patients were randomised to receive pre-oxygenation via a standard facemask or the Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) device. After five minutes of pre-oxygenation, induction and muscle relaxant agents were given. While waiting for complete paralysis, patients in the standard facemask group received bag-mask ventilation (BMV), whereas patients in the HFNO group received apnoeic oxygenation via the THRIVE device. Serial blood samples for arterial blood gas analysis were taken. Baseline patient and airway characteristics were similar. The median PaO 2 after pre-oxygenation was 357 (interquartile range [IQR] 324-450 [range 183-550]) mmHg in the facemask group, compared to 471 (IQR 429-516 [range 185-550]) mmHg in the HFNO group (P=0.01). The median arterial partial pressure of oxygen (PaO 2 ) in the HFNO group decreased after a period of apnoeic oxygenation, and was significantly lower when compared to patients who received BMV in facemask group. The arterial carbon dioxide partial pressure (PaCO 2 ) level after complete paralysis was significantly higher in the HFNO group when compared to the facemask group (median 52 [IQR 48-55 {range 40-65}] versus median 43 [IQR 40-48 {range 35-63}] mmHg, P=0.0005 and P=0.004 respectively). There were no differences in the time to muscle paralysis and time to intubation. Seven patients required use of airway adjuncts during BMV in the facemask group, compared to none in the HFNO group (P=0.004). No complications were observed in either group. HFNO produces a higher PaO 2 after pre-oxygenation and safe PaO 2 during intubation. However, the subsequent fall in PaO 2 and rise in PaCO 2 indicates that it is not as effective as BMV in maintaining oxygenation and ventilation following neuromuscular blockade.
Key Words: alveolar gas exchange, oxygen delivery, factors impacting, oxygen saturation, PaO 2 Desaturation during elective intubation is usually prevented by optimal pre-oxygenation, and continuous bag-mask ventilation (BMV) from the time the patient loses consciousness until complete muscle relaxation is achieved. The standard method of pre-oxygenation is performed using a facemask with an adequate seal between the patient and the circuit. Similarly, to achieve effective BMV during the apnoea time, which can last up to three to four minutes during a non-rapid sequence induction, an adequate facemask seal with a patent airway is required. However, pre-oxygenation and BMV can be challenging in some patients for reasons such as an ineffective seal and poor underlying physiological reserve. Hypoxia can then develop, especially if an unanticipated difficult airway is encountered, which is one of the leading causes of anaesthesia-related morbidity and mortality 1 . The Optiflow™ Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) device (Fisher and Paykel, Auckland, New Zealand) allows warm, humidified oxygen to be delivered at a rate of up to 70 litres per minute via nasal cannulae. Its use in critical care medicine has been gaining popularity 2, 3 . It has been shown in a few studies to be a practicable method for pre-oxygenating patients during rapid sequence induction of general anaesthesia [4] [5] [6] . It has also been shown to prolong apnoea time, when there is no assisted ventilation and no desaturation, when compared to no oxygenation post-induction 7, 8 . In this study, we explored the use of the Optiflow THRIVE device in both pre-oxygenation and apnoeic oxygenation in adults who were intubated following a non-rapid sequence induction. We hypothesised that in adults undergoing elective intubation, the use of THRIVE for pre-oxygenation would result in a higher arterial partial pressure of oxygen (PaO 2 ) level compared to standard facemask ventilation. We also investigated the apnoeic period to determine whether apnoeic oxygenation using the THRIVE device would result in a higher PaO 2 level compared to BMV. In contrast to the facemask technique, the Optiflow THRIVE device does not provide end-tidal carbon dioxide (ETCO 2 ) level feedback. We compared the effectiveness of oxygenation and CO 2 clearance by examining the changes in PaO 2 and arterial partial pressure of carbon dioxide (PaCO 2 ) levels between the two techniques, from the time of anaesthetic induction until complete muscle relaxation and successful intubation. Patients were recruited if they were Englishspeaking, 18 years of age or older, American Society of Anesthesiologists physical status 1 to 3, able to give informed consent, having a neurosurgical operation that required general anaesthesia for asleep orotracheal intubation, and required arterial line insertion preoperatively. In line with the manufacturer's instructions and ethical requirements, patients were excluded if their body mass index was greater than 35 kg/m 2 , if they had a known or anticipated difficult airway, if they required fibreoptic intubation, gas induction or rapid sequence intubation, if they had a known allergy to propofol or rocuronium, if they had significant raised intracranial pressure (determined clinically or radiologically), if they were pregnant, if they had active nasal bleeding, or if they had a base of skull fracture.
Materials and methods
The OptiFlow THRIVE device was used in the high-flow nasal oxygen (HFNO) group. The standard facemask group received oxygen via an anaesthetic facemask and circuit, delivered from a GE Datex-Ohmeda (GE Healthcare, Australia/ New Zealand) anaesthetic machine.
All patients presenting for neurosurgical operations during the study period were screened by one of the investigators (CYT). Randomisation was performed by computer-generated randomisation in blocks of ten. Allocations were concealed by putting the allocation in numbered and sealed envelopes prior to recruitment. Participants, treating anaesthetists and the investigator responsible for recruitment were not aware of the randomisation group prior to consent. The allocation was revealed only after the patient consented to participate in the study. It was not possible to blind participants, the data collector or anaesthetists to the group allocation while the procedure was conducted due to the different appearance of the devices.
After written informed consent was obtained, patients were assigned to have their pre-oxygenation delivered either via a standard facemask or the THRIVE device. The patient's baseline characteristics including age, sex, height, weight, American Society of Anesthesiologists physical status and airway characteristics were recorded preoperatively. An arterial line was inserted before anaesthetic induction. A baseline arterial blood gas (ABG) sample was taken while the patient was breathing room air. Rapid-Insufflation Ventilatory Exchange; BMV, bag-mask ventilation; ABG, arterial blood gas sample; TOF, train-of-four.
After the patient was placed in a sniffing position with a pillow under the head, pre-oxygenation was commenced with appropriate monitoring, resuscitation equipment and assistance in accordance with the Australian and New Zealand College of Anaesthetists guidelines. A bispectral index monitor was applied. The THRIVE device was turned on at least ten minutes prior to the start of induction to ensure the oxygen was humidified sufficiently.
Oxygen was delivered via the device according to the allocation group. In the facemask group, patients received pre-oxygenation from a facemask connected to a circle system connected to the anaesthetic machine with the bag setting selected. Oxygen was delivered at 10 litres per minute with the adjustable pressure-limiting valve fully open. In the HFNO group, the THRIVE device was applied with an initial flow rate of 30 litres per minute for 30 seconds, which was then increased to 50 litres per minute. In both groups, after five minutes of pre-oxygenation, an ABG sample was taken via the arterial line. Anaesthetic induction then commenced ( Figure 1 ).
For anaesthetic induction, propofol was administered using a target-controlled infusion technique aiming to achieve a bispectral index between 40 and 60. Opioids were given at the discretion of the treating anaesthetist. A nerve stimulator was calibrated before muscle relaxant was given, and train-offour count was measured every 20 seconds. Rocuronium was given at 1.0 mg/kg.
In the facemask group, BMV was commenced as soon as the patient lost consciousness. Manual ventilation was maintained to keep the ETCO 2 between 35 to 40 mmHg. In the HFNO group, apnoeic oxygenation via the THRIVE device was continued after the patient lost consciousness. Upper airway patency was maintained to ensure adequate apnoeic oxygenation. Airway manoeuvres such as chin lift and jaw thrust and airway adjuncts such as an oropharyngeal airway could be used in either group at the discretion of the anaesthetist.
Once the train-of-four count count was zero, another ABG sample was taken and then the patient was intubated. After successful intubation, a final ABG sample was taken before mechanical ventilation was commenced. After this time, the anaesthetist could modify the anaesthetic technique at their discretion. If at any stage there was desaturation (peripheral oxygen saturation [SpO 2 ] <95%) or an unanticipated difficult intubation after apnoeic oxygenation, the treating anaesthetist was permitted to manage the airway at his/her own discretion as deemed appropriate, including conversion to BMV if necessary.
All of the ABG samples taken from each patient were transported in a foam cup filled with ice and analysed immediately. After the procedure was complete, a verbal rating satisfaction score was obtained from the anaesthetist. An observer independent of the treating anaesthetic team collected all the relevant data as per the case report form.
Outcomes
The primary outcome was the PaO 2 after five minutes of pre-oxygenation.
Secondary outcomes included the PaO 2 pre-intubation and post-intubation; PaCO 2 at five minutes after pre-oxygenation, pre-intubation and post-intubation; SpO 2 at five minutes after pre-oxygenation, pre-intubation and post-intubation; duration of BMV or apnoeic ventilation before first intubation attempt (=time taken for complete paralysis); time taken for successful intubation; anaesthetists' satisfaction scores using a five-point Likert scale; patient tolerance of the THRIVE device (comfortable, mild discomfort but tolerable, significant discomfort, or intolerable); number of adjuncts used during BMV or apnoeic oxygenation; any complications, including failed BMV or apnoeic oxygenation, failed intubation, need to revert to BMV due to desaturation, hypoxia, arrhythmia, myocardial ischaemia, cardiac or respiratory arrest.
Statistical analysis
Based on a previous study 9 , the standard deviation of PaO 2 was 50 mmHg after pre-oxygenation with normal facemask breathing. We assumed that the PaO 2 would be at least 50 mmHg higher in patients receiving THRIVE than patients receiving mask oxygen for pre-oxygenation. With a standard deviation of 50 mmHg, an alpha error of 0.02 and a power of 0.8, the sample size calculation suggested that a minimum sample size of 16 patients was required in each group. We recruited a total of 50 patients to account for potential dropouts.
A chi-square test was used to examine non-parametric data. The Mann-Whitney U test was used to examine parametric data. A P-value <0.05 was considered statistically significant and corrections for multiple analyses were performed where relevant. Statistical analysis was performed using Stata 13.0 (Statacorp, College Station, TX, USA).
Results
A total of 50 patients consented for the study, with 25 patients randomised to each group. One patient in the standard group was excluded because of protocol violation. One patient in the HFNO group could not tolerate the THRIVE device during the pre-oxygenation phase and was excluded from the study. Data from a total of 48 patients, 24 in each group, were analysed ( Figure 2) . Baseline characteristics and procedural data of the two groups are presented in Table 1 .
The course of the PaO 2 changes is shown in Figure 3 . The primary outcome, being the median PaO 2 after five minutes of pre-oxygenation, was 357 (interquartile range [IQR] 324-450 [range 183-550]) mmHg in the facemask group, and 471 (IQR 429-516 [range 185-550]) mmHg in the HFNO group, a difference that was statistically significant (P=0.03). The PaO 2 level in the HFNO group decreased after the period of apnoeic oxygenation and was significantly lower (P=0.03) when compared to the facemask group details.
The PaCO 2 levels after complete paralysis and after intubation were significantly higher in the HFNO group when compared to the facemask group (P=0.0005 and P=0.04 respectively), despite there being no significant difference between the two groups after five minutes of preoxygenation (Figure 4 ). Figure 5 shows the rate of change of PaCO 2 against PaO 2 of each individual from the time of induction to complete muscle paralysis.
With regard to the secondary outcomes, in the facemask group a significantly higher number of patients required the use of airway adjuncts during BMV and there was a non-significant slightly longer time taken for complete muscle paralysis when compared to apnoeic oxygenation in the HFNO group (Table 2) . One participant found the THRIVE device intolerable, and four participants found it uncomfortable but tolerable. All patients were successfully intubated, but one patient in the HFNO group required BMV after the first intubation attempt failed. No patient in either group had any other complications, including hypoxia (SpO 2 <90%), and none required transfer to a higher level of care.
Discussion
The THRIVE device produced a higher PaO 2 after preoxygenation, presumably because it could provide a stable high FiO 2 , positive end-expiratory pressure effect, washout of anatomical dead space and bypass of a suboptimal seal when compared to the standard facemask pre-oxygenation technique. However, this advantage was lost during the period of apnoea following induction and paralysis. This was most likely due to the fact that effective ventilation was maintained in the facemask group but not in the HFNO group, as evidenced by the significantly higher PaCO 2 in this group. This finding suggests that the THRIVE device as used (at 50 litres per minute) could effectively protect patients from desaturation in the short term, but not completely against hypercarbia.
Our assumption is that the lack of ETCO 2 feedback confirming airway patency in the THRIVE group meant that a number of those patients might have had unrecognised airway obstruction following apnoea and paralysis-therefore they continued to deplete their functional residual capacity oxygen store and failed to have CO 2 egress. Conversely, patients in the facemask group achieved effective gas exchange and hence their PaO 2 levels increased and their PaCO 2 levels were maintained at the desired level. It is alternatively possible that the flow rate used in the study (50 litres per minute) was insufficient to achieve significant CO 2 clearance, contributing to the higher than expected ETCO 2 observed in the THRIVE group. These observations suggest that the most applicable role for the THRIVE device is in pre-oxygenation, perhaps especially in patients who may be difficult to pre-oxygenate effectively with conventional techniques, such as those with beards or other airway pathology. This may be especially pertinent when performing a rapid sequence induction where the apnoeic period is brief, as shown in Lodenius' study 10 
.
The median PaCO 2 level rose between the end of preoxygenation and the onset of complete paralysis. The rise in the facemask group was 4 mmHg, to a level conventionally considered safe of 43 mmHg, while the rise in the HFNO group was 15 mmHg, to a level of 52 mmHg. This CO 2 rise could be deleterious to a patient if THRIVE were being used in the setting of known significantly raised intracranial pressure. Patel et al's observational study in 25 patients using high-flow oxygen insufflation (70 litres per minute) showed that the rate of ETCO 2 rise was approximately 1.13 mmHg/ minute. They attributed the low CO 2 rise to continuous insufflation and carbon dioxide clearance through gaseous mixing and dead space washout. However, other studies have estimated the rate of rise in PaCO 2 with low-flow apnoeic oxygenation (5-10 litres per minute) to be approximately 4.5 mmHg/minute. In our study, the average rate of PaCO 2 rise was approximately 3.06 mmHg/minute, with an oxygen flow rate of 50 litres per minute, based on the PaCO 2 change from anaesthetic induction to just prior to intubation.
This combination of developing oxygen depletion and evolving hypercarbia suggested hypoventilation as the cause, rather than other causes of blood gas derangement such as ventilation/perfusion mismatch (e.g. shunt) which would have produced more marked oxygen depletion and relatively less hypercarbia. Anaesthetists at our centre are experienced in the use of both devices and would routinely attempt to limit the rise in a patient's PaCO 2 up to a maximum value under 45 mmHg for neurosurgical procedures. It was possible that in this trial, the lack of feedback from the ETCO 2 monitor and tactile feedback of adequacy of ventilation led to unappreciated loss of upper airway patency and consequent loss of effective oxygen delivery and CO 2 washout in the HFNO group. This idea was supported by the statistically more likely frequent use of airway adjuncts in the facemask group. This risk may represent a limitation of the THRIVE device, which may be addressed by early identification of those at higher risk of airway obstruction, such as patients with obstructive sleep apnoea. It is possible that other technology, such as transcutaneous CO 2 monitoring, and routine use of airway adjuncts, such as nasopharyngeal airways, in conjunction with the THRIVE device may mitigate this risk. This is supported by Gustafsson's study 11 , which showed that using THRIVE at a high flow rate (70 litres per minute) with confirmation of a patent airway at all times, can keep patients well-oxygenated, but transcutaneous or arterial CO 2 measurement is essential to monitor the rise of CO 2 .
Previous trials have compared THRIVE to facemask preoxygenation in patients who remained spontaneously breathing, or patients who were apnoeic and were not ventilated. This trial contributes to the understanding of gas exchange physiology during the use of THRIVE by comparing THRIVE with BMV after muscle paralysis for non-rapid sequence induction.
The small size of the trial was a limitation. The observed difference in PaO 2 was in fact larger than anticipated. The short time interval between the end of pre-oxygenation and development of complete paralysis was another limitation. If a longer time had elapsed a larger difference between the groups might have been observed.
The trial was a pragmatic, real-world exploration of the role of HFNO during routine induction for neurosurgery. The results should be widely applicable to adults undergoing this procedure. The trial did not enrol children or pregnant women and is unable to guide practice in these groups.
We did not enrol any patients with an anticipated difficult intubation, for which HFNO has sometimes been advocated. Consequently, the trial cannot inform practice for these patients.
Conclusion
The THRIVE device delivered a higher pre-oxygenation during a period of spontaneous ventilation, but this advantage was offset by the subsequent loss of ventilation, and consequent fall in PaO 2 and rise in PaCO 2 during apnoea and paralysis. Thus the THRIVE device is not as effective as BMV in maintaining oxygenation and ventilation following neuromuscular blockade. It is possible that a failure to maintain a patent upper airway contributed to these findings. The lack of feedback regarding the effectiveness of oxygen delivery and CO 2 clearance limits the ability to monitor for this. Future trials should examine the role of airway adjunct devices and the role of transcutaneous CO 2 monitoring to alert anaesthetists to the absence of airway patency when using the THRIVE device.
The results of this trial suggest that maintenance of effective ventilation after pre-oxygenation is important to limit the depletion of functional residual capacity oxygen stores and to continue to facilitate CO 2 exchange. The THRIVE device appears effective in maintaining PaO 2 above a safe threshold during routine relaxant general anaesthetic intubation. As a result, the THRIVE device may be most suitable for use during pre-oxygenation, particularly for rapid sequence induction where the apnoeic time is short, and in patients who are difficult to pre-oxygenate or mask ventilate by conventional means.
